Refine by
Clinical Safety Articles & Analysis
75 news found
Adial announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD). The publication also reported the results of ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. ...
To request a meeting, please contact Cingulate Investor Relations at mkreps@darrowir.com. The Phase 3 clinical trial is an adult dose-optimization study to assess the onset and duration of efficacy along with the safety of CTx-1301 in adults with ADHD compared to placebo. ...
Complementing the Explorer, they provide open access to information from a variety of areas, including clinical trials and safety studies of Bayer’s crop protection products, or its political activities. ...
ByBayer AG
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG ...
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. ...
It is also the only device producing an IAEA-compliant BNCT beam for the effective and safe clinical use of neutrons. During the commissioning process, the Helsinki nuBeam® device has demonstrated both robustness and reliable operation, validating Neutron Therapeutics’ technology as the best choice for high-throughput BNCT clinics with stringent ...
Elizabeth Holt, Head of Global Medical, Clinical, and Safety, LifeScan. “These data suggest the potential benefits of integrating easy to use tools into patients’ day-to-day routines that give them an understanding of what their blood glucose numbers mean, actions they can take, and the encouragement to help them stay on ...
ByLifeScan
” Over the last two decades, disease activity in rheumatoid arthritis (RA) has improved, yet fatigue and pain continue to hinder patients’ quality of life (QOL), and ability to function.2,3 Less than 30% of patients are satisfied with their pain levels and 40-80% of RA patients are affected by fatigue.4,5 Pain and fatigue have negative impacts on mental and physical QOL, including ...
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. ...
In addition, HIFU ultrasound machine therapy has been approved by the FDA after clinical safety research, and has been implemented all over the world. ...
Yvonne Achermann is planning further clinical research on the safety and efficacy of the PJI treatment. PJIs are most commonly caused by the bacteria Staphylococcus aureus (S. ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives ...
William Welch, MD of the University of Pennsylvania and co-principal investigator of the LimiFlexIDE study added, "I am encouraged by the clinical outcomes and results we have seen so far in the study. LimiFlex is an exciting new possibility for patients currently undergoing fusion for degenerative spondylolisthesis and would offer much faster recovery for patients, significant ...
The resulting constructs reduce spinal flexibility and magnify the forces experienced by adjacent levels, often leading to accelerated degeneration of the adjacent spinal segments. While the acute clinical outcomes may be excellent, this accelerated degeneration can lead to longer term issues, sometimes requiring additional surgery. ...
The resulting constructs reduce spinal flexibility and magnify the forces experienced by adjacent levels, often leading to accelerated degeneration of the adjacent spinal segments. While the acute clinical outcomes may be excellent, this accelerated degeneration can lead to longer term issues, sometimes requiring additional surgery. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
“This sets the stage for the rest of the year, as we anticipate moving two programs into the clinic using our existing RaniPill capsule, while also advancing development of the RaniPill HC for high-dose biologics. ...